International Biotechnology (IBT) Competitors GBX 648 0.00 (0.00%) As of 08/7/2025 11:53 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock IBT vs. RICA, SAIN, CGT, MUT, JEO, APEO, SLPE, ESCT, BLU, and SDPShould you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include Ruffer Investment (RICA), Scottish American Investment (SAIN), Capital Gearing (CGT), Murray Income Trust (MUT), European Opportunities Trust (JEO), abrdn Private Equity Opportunities (APEO), Standard Life Private Equity Trust (SLPE), The European Smaller Companies Trust (ESCT), Blue Star Capital (BLU), and Schroder Investment Trust - Schroder AsiaPacific Fund (SDP). These companies are all part of the "asset management" industry. International Biotechnology vs. Its Competitors Ruffer Investment Scottish American Investment Capital Gearing Murray Income Trust European Opportunities Trust abrdn Private Equity Opportunities Standard Life Private Equity Trust The European Smaller Companies Trust Blue Star Capital Schroder Investment Trust - Schroder AsiaPacific Fund Ruffer Investment (LON:RICA) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk. Does the media refer more to RICA or IBT? In the previous week, International Biotechnology had 1 more articles in the media than Ruffer Investment. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Ruffer Investment. Ruffer Investment's average media sentiment score of 0.00 equaled International Biotechnology'saverage media sentiment score. Company Overall Sentiment Ruffer Investment Neutral International Biotechnology Neutral Which has more risk & volatility, RICA or IBT? Ruffer Investment has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, International Biotechnology has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Do institutionals and insiders believe in RICA or IBT? 43.3% of Ruffer Investment shares are owned by institutional investors. Comparatively, 45.2% of International Biotechnology shares are owned by institutional investors. 0.2% of Ruffer Investment shares are owned by insiders. Comparatively, 4.2% of International Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, RICA or IBT? International Biotechnology has higher revenue and earnings than Ruffer Investment. International Biotechnology is trading at a lower price-to-earnings ratio than Ruffer Investment, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRuffer Investment£16.91M54.24£8.78M£2.75103.67International Biotechnology£41.82M5.57£37.91M£104.806.18 Is RICA or IBT a better dividend stock? Ruffer Investment pays an annual dividend of GBX 5 per share and has a dividend yield of 1.8%. International Biotechnology pays an annual dividend of GBX 29 per share and has a dividend yield of 4.5%. Ruffer Investment pays out 181.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. International Biotechnology pays out 27.7% of its earnings in the form of a dividend. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio. Is RICA or IBT more profitable? International Biotechnology has a net margin of 90.66% compared to Ruffer Investment's net margin of 51.94%. International Biotechnology's return on equity of 13.67% beat Ruffer Investment's return on equity.Company Net Margins Return on Equity Return on Assets Ruffer Investment51.94% 0.96% 0.45% International Biotechnology 90.66%13.67%3.57% SummaryInternational Biotechnology beats Ruffer Investment on 11 of the 14 factors compared between the two stocks. Get International Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBT vs. The Competition Export to ExcelMetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£232.77M£1.29B£6.35B£3.07BDividend Yield4.20%4.41%4.19%5.02%P/E Ratio6.1822.3914.17167.05Price / Sales5.572,589.191,871.99328,748.11Price / Cash155.7460.70127.2427.97Price / Book0.851.432.254.52Net Income£37.91M£265.04M£1.23B£5.90B7 Day Performance1.89%0.58%0.95%1.33%1 Month Performance8.36%0.77%2.23%3.77%1 Year Performance-2.70%8.11%26.60%57.72% International Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBTInternational BiotechnologyN/AGBX 648flatN/A-2.7%£232.77M£41.82M6.18N/ANews CoverageHigh Trading VolumeRICARuffer InvestmentN/AGBX 285+0.2%N/A-0.9%£917.06M£16.91M103.67N/ASAINScottish American InvestmentN/AGBX 516.14+0.2%N/A+0.7%£902.51M£75.38M10.35N/AEarnings ReportCGTCapital GearingN/AGBX 4,830-0.2%N/A+2.7%£898.26M£17.92M19.64N/ANews CoverageMUTMurray Income TrustN/AGBX 894.46-0.6%N/A+2.9%£893.64M£97.96M9.86147,000Positive NewsDividend CutJEOEuropean Opportunities TrustN/AN/AN/AN/A£886.70M-£62.33M-12.93N/AAPEOabrdn Private Equity OpportunitiesN/AN/AN/AN/A£880.29M£80.21M1,435.00N/ASLPEStandard Life Private Equity TrustN/AGBX 558+1.5%N/A+2.3%£857.90M£251.60M3.60N/AESCTThe European Smaller Companies TrustN/AGBX 215.50-0.2%N/A+22.1%£850.01M£96.24M10.16305Positive NewsBLUBlue Star CapitalN/AGBX 16.53-2.8%N/A+99,275.0%£841.38M-£5.16M1.903SDPSchroder Investment Trust - Schroder AsiaPacific FundN/AGBX 593-0.2%N/A+15.5%£837.71M£134.70M6.92N/APositive News Related Companies and Tools Related Companies Ruffer Investment Competitors Scottish American Investment Competitors Capital Gearing Competitors Murray Income Trust Competitors European Opportunities Trust Competitors abrdn Private Equity Opportunities Competitors Standard Life Private Equity Trust Competitors The European Smaller Companies Trust Competitors Blue Star Capital Competitors Schroder Investment Trust - Schroder AsiaPacific Fund Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:IBT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding International Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share International Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
